Tatar Gamze, Beyhan Ediz, Erol Fenercioğlu Özge, Sevindir İsa, Ergül Nurhan, Çermik Tevfik Fikret
University of Health Sciences Turkey, İstanbul Bağcılar Training and Research Hospital, Clinic of Nuclear Medicine, İstanbul, Turkey.
University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Nuclear Medicine, İstanbul, Turkey.
Mol Imaging Radionucl Ther. 2023 Jun 20;32(2):146-149. doi: 10.4274/mirt.galenos.2022.80774.
Fibroblast activation protein (FAP) is expressed as a pro-inflammatory agent from fibrous tissue in liver cirrhosis and in the tumor microenvironment. Cirrhosis is the last stage of any chronic liver disease, and the natural course of cirrhosis is the progression from the asymptomatic phase to the symptomatic decompensated phase with the development of ascites. Although various clinical features suggest cirrhosis in patients with chronic liver disease, non-invasive methods should follow the clinical approach before a definitive diagnosis. Herein, we present three cases of liver cirrhosis with fibroblast activation protein inhibitor (FAPI) uptake to demonstrate the usefulness of Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) scan in cirrhosis.
成纤维细胞活化蛋白(FAP)在肝硬化的纤维组织以及肿瘤微环境中作为一种促炎因子表达。肝硬化是任何慢性肝病的终末期,肝硬化的自然病程是从无症状期发展到出现腹水的有症状失代偿期。尽管各种临床特征提示慢性肝病患者患有肝硬化,但在明确诊断之前,非侵入性方法应遵循临床路径。在此,我们展示三例有纤维母细胞活化蛋白抑制剂(FAPI)摄取的肝硬化病例,以证明镓[Ga]FAPI-04正电子发射断层扫描/计算机断层扫描(PET/CT)在肝硬化诊断中的作用。